The dual inhibitors AZD8055, Sapanisertib (INK128), and Torin-1 achieve more comprehensive mTOR inhibition and exhibit antitumor efficacy in preclinical glioma models [127,129]. This evidence concerns the gene MTOR and central nervous system cancer.